Stock CVAC CUREVAC N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
3.13 USD +13.00% Intraday chart for CureVac N.V. +34.33% -25.65%
05-02 CUREVAC : A missed opportunity Alphavalue
04-26 UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK
AQ
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQ
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
EQ
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
EQ
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
EQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
AQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
EQ
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
EQ
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
EQ
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
AQ
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
EQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K
PU
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
EQ
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
EQ
CureVac N : to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023
PU
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
EQ
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
EQ
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
AQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K
PU
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. News CureVac N.V.
  5. Press Releases